Recent FDA Approvals in dMMR Solid Tumors and von Hippel Lindau–Associated Cancers

This week, we’ll be reviewing two recent FDA approvals in the oncology space, for patients with mismatch repair–deficient, or dMMR, recurrent or advanced solid tumors, and for adult patients with cancers associated with von Hippel-Lindau disease.

---